Table 2.

Summary of upcoming therapeutic agents for NAFL/NASH.

Treatment strategy	Medication	Comment
Bile Acid Receptors (FXR)	OCA	Has been shown to improve aminotransferases, insulin resistance, and NAS but can worsen lipid panel [84, 85]
PPAR alpha/delta agonist	Elafibranor	Can improve metabolic risk factors and lead to resolution of NASH [https://clinicaltrials.gov   NCT01694849]
Other agents	Cysteamine bitartrate, caspase inhibitor, and simtuzumab	Had promising results in phase 2 trials and some are still undergoing clinical trials

FXR: farnesoid receptor; OCA: obeticholic acid.